Cardiac Neuronal Imaging at the Edge of Clinical Application

Cardiology Clinics

Volumn 27, Issue 2, 2009, Pages 311-327

  Travin, Mark I ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Autonomic; Cardiac; HED; Imaging; MIBG; Nuclear

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; 3 HYDROXYEPHEDRINE C 11; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE C 11; 4 FLUOROBENZYLGUANIDINE F 18; 6 FLUORODOPAMINE F 18; 6 FLUORONOREPINEPHRINE F 18; ADRENALIN C 11; BISOPROLOL C 11; CGP 12388 C 11; CGP 26505 C 11; DOXORUBICIN; FLUORO DEOXY GLUCOSE 3 (2 AZETIDINYLMETHOXY)PYRIDINE F 18; FLUOROCARAZOLOL F 18; FLUOROIDOBENZYLGUANIDINE F 18; FLUOROMETARAMINOL F 18; FORMOTEROL C 11; GB 67 C 11; METABROMOBENZYLGUANIDINE BR 76; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METOPROLOL; MYOSIN ANTIBODY IN 111; PHENYLEPHRINE C 11; POSTSYNAPTIC RECEPTOR; PRAZOSIN C 11; PROCATEROL C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANATOMY; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DIABETES MELLITUS; HEALTH CARE COST; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMAGING; ISCHEMIC HEART DISEASE; NERVE CELL; NEUROIMAGING; NONHUMAN; PARASYMPATHETIC FUNCTION; PARASYMPATHETIC TONE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION;

3-IODOBENZYLGUANIDINE; AUTONOMIC NERVOUS SYSTEM; HEART; HUMANS; MYOCARDIUM; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; STROKE VOLUME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 62749161100     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.12.007     Document Type: Review

References (98)

1. Carrió I. Cardiac neurotransmission imaging. J Nucl Med 42 7 (2001) 1062-1076
2. Zipes D.P. Autonomic Modulation of Cardiac Arrhythmias. In: Zipes D.P., and Jalife J. (Eds). Cardiac electrophysiology: from cell to bedside. 2nd edition (1995), W.B. Saunders Company, Philadelphia 441-442
3. Flotats A., and Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 11 (2004) 587-602
4. Verrier R.L., and Antzelevich C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol 19 (2004) 2-11
5. Bengel F.M., and Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol 11 (2004) 603-616
6. Sisson J.C., and Wieland D.M. Radiolabelled meta-iodobenzylguanidine pharmacology: pharmacology and clinical studies. Am J Physiol Imaging 1 (1986) 96-103
7. Goldstein D.S., Holmes C.S., Dendi R., et al. Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58 (2002) 1247-1255
8. Kline R.C., Swanson D.P., Wieland D.M., et al. Myocardial imaging in man with I-123 metaiodobenzylguanidine. J Nucl Med 22 (1981) 129-132
9. Wieland D.M., Brown L.E., Rogers W.L., et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 22 (1981) 22-31
10. Hattori N., and Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart. What have we learned clinically?. Eur J Nucl Med 27 (2000) 1-6
11. 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med 46 (2005) 1368-1374
12. Lautamäki R., Tipre D., and Bengel F.M. Cardiac sympathetic neuronal imaging using PET. Eur J Nucl Med Mol Imaging 34 (2007) S74-S85
13. Langer O., and Halldin C. PET and SPECT tracers for mapping the cardiac nervous system. Eur J Nucl Med Mol Imaging 29 (2002) 416-434
14. Patel A.D., and Iskandrian A.E. MIBG imaging. J Nucl Cardiol 9 (2002) 75-94
15. Chen J.I., Garcia E.V., Galt J.R., et al. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol 13 (2006) 251-260
16. Minardo J.D., Tuli M.M., Mock B.H., et al. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 78 (1988) 1008-1019
17. 123I-MIBG scintigraphic study. J Nucl Med 41 (2000) 845-851
18. 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 86 (2001) 656-660
19. Yamada T., Shimonagata T., Fukunami M., et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. J Am Coll Cardiol 41 (2003) 231-238
20. Somsen G.A., Verberne H.J., Fleury E., et al. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol 11 (2004) 126-133
21. Gill J.S., Hunter G.J., Gane G., et al. Heterogeneity of the human myocardial sympathetic innervation: in vivo demonstration by iodine 123-labeled metaiodobenzylguanidine scintigraphy. Am Heart J 126 (1993) 390-398
22. Morozumi T., Kusuoka H., Fukuchi K., et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med 38 (1997) 49-52
23. Tsuchimochi S., Tamaki N., Tadamura E., et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med 36 (1995) 969-974
24. Estorch M., Serra-Grima R., Flotats A., et al. Myocardial sympathetic innervation in the athlete's sinus bradycardia: is there selective inferior myocardial wall denervation?. J Nucl Cardiol 7 (2000) 354-358
25. Bülow H.H., Nekolla S.G., Schwaiger M., et al. Comparison of the normal distribution of three tracers used for evaluation of the presynaptic sympathetic neuron. J Nucl Cardiol 10 (2003) S44
26. Udelson J.E., Shafer C.D., and Carrió I. Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management. J Nucl Cardiol 9 (2002) S40-S52
27. Chen G.P., Tabibiazar R., Branch K.R., et al. Cardiac receptor physiology and imaging: an update. J Nucl Cardiol 12 (2005) 714-730
28. Kioka H., Yamada T., Mine T., et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart 93 (2007) 1213-1218
29. Anastasiou-Nana M.I., Terrovitis J.V., Athanasoulis T., et al. Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 96 (2005) 427-431
30. Arimoto T., Takeishi Y., Niizeki T., et al. Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure. J Card Fail 13 (2007) 34-41
31. Merlet P., Benvenuti C., Moyse D., et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 40 (1999) 917-923
32. Merlet P., Valette H., Dubois-Randé J., et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med 33 (1992) 471-477
33. Nakata T., Miyamoto K., Doi A., et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 5 (1998) 579-590
34. Agostini D., Verberne H.J., Burchert W., et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 35 (2008) 535-546
35. Jacobson A.F., Lombard J., Banerjee G., et al. 123-I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol 16 (2009) 113-121
36. Wakabayashi T., Nakata T., Hashimoto A., et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 42 (2001) 1757-1767
37. 123I-MIBG in the failing human heart. J Nucl Med 40 (1999) 224-231
38. 123I-metaiodobenzylguanidine uptake. J Nucl Med 42 (2001) 49-54
39. Cohen-Solal A., Rouzet F., Berdeaux A., et al. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med 46 (2005) 1796-1803
40. Gerson M.C., Craft L.L., McGuire N., et al. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 9 (2002) 608-615
41. Takeishi Y., Atsumi H., Fujiwara S., et al. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 38 (1997) 1085-1089
42. 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 40 (1999) 217-223
43. Kasama S., Toyama T., Kumakura H., et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 44 (2003) 884-890
44. Kasama S., Toyama T., Kumakura H., et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 43 (2002) 1279-1285
45. Toyama T., Hoshizaki H., Seki R., et al. Efficacy of amiodarone treatment on cardiac symptom, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: comparison with β-blocker therapy. J Nucl Cardiol 11 (2004) 134-141
46. Suwa M., Otake Y., Moriguchi A., et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 133 (1997) 353-358
47. Choi J.Y., Lee K.H., Hong K.P., et al. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol 8 (2001) 4-9
48. 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments-comparison with neurohumoral factors. Circ J 66 (2002) 537-543
49. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
50. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
51. Yu C.M., Zhang Q., Fung J.W., et al. A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging. J Am Coll Cardiol 45 (2005) 677-684
52. 123I-MIBG myocardial scintigraphy. J Nucl Cardiol 14 (2007) 852-859
53. Tomaselli G.F., and Zipes D.P. What causes sudden death in heart failure?. Circ Res 95 (2004) 754-763
54. Zipes D.P., Camm A.J., Borggrefe M., et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death-executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol 48 (2006) 1064-1108
55. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
56. Fisher J.D., and Hector H.E. Relative and absolute benefits: main results should be reported in absolute terms. Pacing Clin Electrophysiol 30 (2007) 935-937
57. Buxton A.E., Lee K.L., Hafley G.E., et al. For the MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease. J Am Coll Cardiol 50 (2007) 1150-1157
58. Sanders G.D., Hlatky M.A., and Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 353 (2005) 1471-1480
59. Barron H.V., and Lesh M.D. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 27 (1996) 1053-1060
60. Stanton M.S., Tuli M.M., Radtke N.L., et al. Regional sympathetic denervation after MI in humans detected noninvasively using I-123-MIBG. J Am Coll Cardiol 14 (1989) 1519-1526
61. McGhie A.I., Corbett J.R., Akers M.S., et al. Regional cardiac adrenergic function using I-123 MIBG SPECT imaging after acute myocardial infarction. Am J Cardiol 67 (1991) 236-242
62. Arora R., Ferrick K.J., Nakata T., et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 10 (2003) 121-131
63. Nagahara D., Nakata T., Hashimoto A., et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 49 (2008) 225-233
64. Exner D.V., Klein G.J., and Prystowsky E.N. Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: can we afford to do it? (Can we afford not to?). Circulation 104 (2001) 1564-1570
65. Chow T., Kereiakes D.J., Bartone C., et al. Microvolt T-wave alternans identified patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy. J Am Coll Cardiol 49 (2007) 50-58
66. Wilson R.F., Christensen B.V., Olivari M.T., et al. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans. Circulation 38 (1991) 1210-1220
67. Hunt S. Reinnervation of the transplanted heart-why is it important?. N Engl J Med 345 (2001) 762-764
68. Schwaiger M., Hutchins G.D., Kalff V., et al. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest 87 (1991) 1681-1690
69. Bengel F.M., Ueberfuhr P., Ziegler S.I., et al. Serial assessment of sympathetic reinnervation after orthotopic heart transplantation. A longitudinal study using PET and C-11 hydroxyephedrine. Circulation 99 (1999) 1866-1871
70. Bengel F.M., Ueberfuhr P., Schiepel N., et al. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med 345 (2001) 731-738
71. Zipes D.P. Influence of myocardial ischemia and infarction on autonomic innervation of heart. Circulation 82 (1990) 1095-1105
72. Dae M.W., Herre J.M., O'Connell J.W., et al. Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol 17 (1991) 1416-1423
73. Matsunari I., Schricke U., Bengel F.M., et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndrome. Circulation 101 (2000) 2579-2585
74. 123I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med 40 (1999) 904-910
75. Simões M.V., Barthel P., Matsunari I., et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 25 (2004) 551-557
76. Sasano T., Abraham R., Chang K.C., et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol 51 (2008) 2266-2275
77. Kawai Y., Tsukamoto E., Nozaki Y., et al. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol 38 (2001) 1888-1894
78. 123I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 112 (2005) 2169-2174
79. Tomoda H., Yoshioka K., Shiina Y., et al. Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina. Am Heart J 128 (1994) 452-458
80. Watanabe K., Takahashi T., Miyajima S., et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med 43 (2002) 1476-1481
81. Simula S., Vanninen E., Viitanen L., et al. Cardiac adrenergic innervation is affected in asymptomatic subjects with very early stage of coronary disease. J Nucl Med 43 (2002) 1-7
82. Ewing D.J., Campbell I.W., and Clarke B.F. The natural history of diabetic autonomic neuropathy. QJM 49 (1980) 95-108
83. Dyrberg T., Benn J., Christianses J.S., et al. Prevalence of autonomic neuropathy measured by simple bedside tests. Diabetologia 20 (1981) 190-194
84. Langer A., Freeman M.R., Josse R.G., et al. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 25 (1995) 610-618
85. Hattori N., Tamaki N., Hayashi T., et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med 27 (1996) 1985-1990
86. Stevens M.J., Raffel D.M., Allman K.C., et al. Cardiac sympathetic dysinnervation in diabetes. Implications for enhanced cardiovascular risk. Circulation 98 (1998) 961-968
87. Nagamachi S., Fujita S., Nishii R., et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 13 (2006) 34-42
88. Huikuri H.V., Castellanos A., and Myerburg R.J. Sudden death due to cardiac arrhythmias. N Engl J Med 345 (2001) 1473-1482
89. Mitrani R.D., Klein L.S., Miles W.M., et al. Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol 22 (1993) 1344-1353
90. 123I] meta-iodobenzylguanidine scans in patients with ventricular tachycardia and a "clinically normal" heart. Br Heart J 69 (1993) 6-13
91. Schäfers M., Lerch H., Wichter T., et al. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia. J Am Coll Cardiol 32 (1998) 181-186
92. Wichter T., Matheja P., Eckardt L., et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 105 (2002) 702-706
93. Wakasugi S., Fischman A.J., Babich J.W., et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 34 (1993) 1282-1286
94. 123I]Metaiodobenzylguanidine scintigraphy. Eur J Cancer 31 (1995) 26-31
95. Carrió I., Estorch M., Berná L., et al. Assessment of anthracycline-related myocardial adrenergic Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 36 (1995) 2024-2049
96. Caldwell J.H., Link J.M., Levy W.C., et al. Evidence for pre- to postsynaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure. J Nucl Med 49 (2008) 234-241
97. Arora R., Ng J., Ulphani J., et al. Unique autonomic profile of the pulmonary veins and posterior left atrium. J Am Coll Cardiol 49 (2007) 1340-1348
98. Lellouche N., Buch E., Celigoj A., et al. Functional characterization of atrial electrograms in sinus rhythm delineates sites of parasympathetic innervation in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 50 (2007) 1324-1331